Cytek Biosciences Inc

Cytek Biosciences Inc

CTKB · NASDAQ · Healthcare / Medical Devices

5.84USD+0.32 (+5.80%)

Price History

Full chart

Market Stats

Previous Close5.52
Open5.55
Day Range5.41 – 5.87
52-Week Range3.28 – 6.18
Volume1.28M
Market Cap744.80M
P/E (TTM)0.00
Forward P/E370.37
EPS-0.63
Dividend Yield0.00%
Beta1.19
50-Day Avg4.67
200-Day Avg4.58

About

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEODr. Wenbin Jiang Ph.D.
  • Employees682
  • Headquarters47215 Lakeview Blvd, Fremont, CA, United States, 94538-6407, USA
  • Websitehttps://cytekbio.com

Leadership

  • Dr. Wenbin Jiang Ph.D.President, CEO & Chairman of the Board · b. 1964
  • Mr. William D. McCombeChief Financial Officer · b. 1958
  • Dr. Ming Yan Ph.D.CTO & Director · b. 1963
  • Mr. Paul D. GoodsonHead of Investor Relations
  • Mr. Ilan B. FeuchtwangChief Legal Officer
  • Mr. Patrik Sebastian JeanmonodHead of Corporate Development Analytics · b. 1966

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue57.88M92.84M127.95M164.04M193.01M200.45M201.49M
Growth (%)-+60.39%+37.82%+28.20%+17.67%+3.85%+0.52%
Cost of Revenue29.21M41.13M48.81M63.06M83.59M89.35M97.03M
Gross Profit28.67M51.71M79.14M100.97M109.43M111.11M104.46M
Gross Margin49.54%55.70%61.86%61.56%56.69%55.43%51.84%
Operating Expense45.93M38.05M69.99M102.78M137.27M131.63M144.84M
Operating Income-17.26M13.66M9.16M-1.80M-27.84M-20.52M-40.38M
Operating Margin-29.81%14.71%7.16%-1.10%-14.43%-10.24%-20.04%
EBITDA-15.98M15.37M8.92M9.49M-4.41M4.79M-17.39M
EBITDA Margin-27.61%16.55%6.97%5.79%-2.28%2.39%-8.63%
Net Income-16.83M19.41M3.00M2.58M-12.15M-6.02M-66.54M
Net Income Margin-29.07%20.91%2.35%1.57%-6.29%-3.00%-33.02%
R&D8.93M13.69M24.44M34.86M44.15M39.40M36.47M
R&D as % of Total Revenue15.43%14.75%19.10%21.25%22.87%19.66%18.10%
Interest Expense1.00K333.00K1.74M2.57M2.07M5.24M474.00K
Interest Expense % of Total Revenue0.00%0.36%1.36%1.57%1.07%2.61%0.24%

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets70.36M219.98M463.31M519.48M494.46M499.50M461.54M
Total Liabilities112.06M236.01M57.92M93.93M101.39M103.76M119.80M
Total Equity-41.70M-16.03M405.04M425.30M393.06M395.74M341.74M
Cash30.12M165.23M364.62M296.60M167.30M98.72M90.85M
Total Debt-2.77M-18.09M14.14M17.02M23.74M
Net Debt-30.12M-162.46M-364.62M-278.51M-153.16M-81.70M-67.11M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-13.75M15.16M4.63M-12.23M5.28M25.38M-4.69M
Investing Cash Flow-973.00K-1.55M-20.99M-55.91M-93.89M-82.97M10.12M
Financing Cash Flow93.00K122.61M213.56M5.51M-41.81M-15.82M-13.43M
Capital Expenditure973.00K1.55M4.36M9.87M4.83M3.52M4.08M
Free Cash Flow-14.72M13.61M266.00K-22.10M454.00K21.85M-8.77M
Dividends Paid---209.00K1.47M--
FCF to OCF107.08%89.79%5.75%180.68%8.60%86.11%187.15%
Dividend Paid to FCF----0.95%323.35%--

Earnings

Report DateMar 31, 2020Jun 2, 2021Sep 3, 2021Nov 8, 2021Feb 23, 2022May 11, 2022Aug 10, 2022Nov 9, 2022Feb 28, 2023May 9, 2023Aug 8, 2023Nov 7, 2023Feb 28, 2024May 8, 2024Aug 6, 2024Nov 5, 2024Feb 27, 2025May 8, 2025Aug 6, 2025Nov 5, 2025Feb 26, 2026May 7, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.000.000.020.020.030.020.040.030.050.030.020.020.01-0.040.010.040.110.01-0.01-0.05-0.04-0.08-0.06-0.05
EPS Actual-0.030.000.070.010.03-0.020.030.040.06-0.05-0.03-0.010.04-0.01-0.010.060.12-0.03-0.01-0.04-0.04-0.10-0.09-
Surprise--250.00%-50.00%0.00%-200.00%-25.00%33.33%20.00%-266.67%-250.00%-150.00%300.00%75.00%-200.00%50.00%9.82%-400.00%0.00%20.00%0.00%-25.00%-50.00%-
Timing--Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap744.80M
Enterprise Value502.76M
Trailing P/E0.00
Forward P/E370.37
Price / Sales3.60
Price / Book2.29
EPS-0.63
Book Value2.48
Revenue (TTM)206.71M
Gross Profit (TTM)107.23M
EBITDA-39.76M
Profit Margin-38.98%
Operating Margin-29.50%
Return on Equity-23.04%
Return on Assets-6.31%
Shares Outstanding129.98M
Shares Float102.94M
Beta1.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 6 analystsTarget 5.56
  • Strong Buy
    1
  • Buy
    1
  • Hold
    3
  • Sell
    1

Ownership Breakdown

Institutions
63.05%
Insiders
8.47%
Retail / Other
28.48%

Top Institutional Holders

  • BlackRock Inc
    17.01M13.08%
  • Millennium Management LLC
    9.34M7.18%
  • Boston Partners Global Investors, Inc
    7.66M5.89%
  • Hillhouse Capital Advisors, Ltd.
    6.66M5.12%
  • Topline Capital Management LLC
    6.28M4.83%
  • Vanguard Capital Management, LLC
    4.76M3.66%
  • State Street Corp
    4.12M3.17%
  • Geode Capital Management, LLC
    2.83M2.18%
  • Dimensional Fund Advisors, Inc.
    2.62M2.01%
  • The Goldman Sachs Group Inc
    2.34M1.80%
  • Vanguard Portfolio Management, LLC
    2.31M1.78%
  • Morgan Stanley - Brokerage Accounts
    1.72M1.32%
  • Royce & Associates, LP
    1.64M1.26%
  • Charles Schwab Investment Management Inc
    1.10M0.85%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    3.53M2.71%
  • iShares Russell 2000 ETF
    3.12M2.40%
  • Column Small Cap Select
    2.61M2.01%
  • Royce Micro-Cap Trust
    1.32M1.02%
  • Fidelity Small Cap Index
    1.32M1.01%
  • iShares Russell 2000 Value ETF
    1.13M0.87%